Trial reportArthritis and rheumatism2010
Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.
Trial report in Arthritis and rheumatism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 202 citations in OpenAlex.
- Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis.Rheumatology international · 2013Trial
- Ibero-American consensus on reactive arthritis: definition, diagnosis, and management.Clinical rheumatology · 2026Article
- Article
- Reactive arthritis: a comprehensive journey through diagnostic findings.Skeletal radiology · 2025Review
- Antibiotics for Rheumatologic Diseases: A Critical Review.International journal of molecular sciences · 2025Review
- Nontuberculous Mycobacterial Lung Disease Management in Belgium: A Longitudinal Pharmacy Database Study.Drugs - real world outcomes · 2025Article
- [Reactive arthritis].Zeitschrift fur Rheumatologie · 2025Review
- YouTube as a source of information on reactive arthritis: a quality analysis.Zeitschrift fur Rheumatologie · 2024Article
- The menace within: bacterial amyloids as a trigger for autoimmune and neurodegenerative diseases.Current opinion in microbiology · 2024Review
- Review
- Systemic Mastocytosis: A Mimicker of Reactive Arthritis.Case reports in rheumatology · 2023Article
- Poncet's Disease (Reactive Arthritis Associated with Tuberculosis).Internal medicine (Tokyo, Japan) · 2022Article
- [History of reactive arthritis. Historical milestones and future].Zeitschrift fur Rheumatologie · 2022Article
- A flux-based machine learning model to simulate the impact of pathogen metabolic heterogeneity on drug interactions.PNAS nexus · 2022Article
- Expanding the spectrum of reactive arthritis (ReA): classic ReA and infection-related arthritis including poststreptococcal ReA, Poncet's disease, and iBCG-induced ReA.Rheumatology international · 2021Review
- [Postinfectious reactive arthritis after chlamydia infection in competitive sports : Clinical management and current literature review].Der Orthopade · 2021Review
- Outcomes of Antibiotics in Adults with "Difficult to Treat" Asthma or the Overlap Syndrome.Journal of asthma and allergy · 2021Article
- Microbes, helminths, and rheumatic diseases.Best practice & research. Clinical rheumatology · 2020Review
- Reactive Arthritis: Treatment Challenges and Future Perspectives.Current rheumatology reports · 2020Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveChlamydia trachomatis and Chlamydophila (Chlamydia) pneumoniae are known triggers of reactive arthritis (ReA) and exist in a persistent metabolically active infection state in the synovium, suggesting that they may be susceptible to antimicrobial agents. The goal of this study was to investigate whether a 6-month course of combination antibiotics is an effective treatment for patients with chronic Chlamydia-induced ReA.
methodsThis study was a 9-month, prospective, double-blind, triple-placebo trial assessing a 6-month course of combination antibiotics as a treatment for Chlamydia-induced ReA. Eligible patients had to be positive for C trachomatis or C pneumoniae by polymerase chain reaction (PCR). Groups received 1) doxycycline and rifampin plus placebo instead of azithromycin; 2) azithromycin and rifampin plus placebo instead of doxycycline; or 3) placebos instead of azithromycin, doxycycline, and rifampin. The primary end point was the number of patients who improved by 20% or more in at least 4 of 6 variables without worsening in any 1 variable in both combination antibiotic groups combined and in the placebo group at month 6 compared with baseline.
resultsThe primary end point was achieved in 17 of 27 patients (63%) receiving combination antibiotics and in 3 of 15 patients (20%) receiving placebo. Secondary efficacy end points showed similar results. Six of 27 patients (22%) randomized to combination antibiotics believed that their disease went into complete remission during the trial, whereas no patient in the placebo arm achieved remission. Significantly more patients in the active treatment group became negative for C trachomatis or C pneumoniae by PCR at month 6. Adverse events were mild, with no significant differences between the groups.
conclusionThese data suggest that a 6-month course of combination antibiotics is an effective treatment for chronic Chlamydia-induced ReA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.